Conventional treatments, including chemotherapy, immunotherapy, targeted therapy and radiotherapy, are effective clinical strategies for non-small cell lung cancer (NSCLC) patients, which can significantly improve life quality and prolong survival time. However, the application of drugs in NSCLC patients inevitably leads to therapeutic resistance. In recent years, many studies have shown that histone methyltransferases (HMTs), including both protein arginine methyltransferases (PRMTs) and lysine methyltransferases (KMTs), play pivotal roles in tumor initiation, progression, and treatment resistance. This review synthesizes current insights into histone methylation dynamics driving therapeutic resistance, with a focus on key HMTs and their mechanisms. Additionally, we discuss the molecular mechanisms underlying histone methylation-mediated therapeutic resistance and potential therapeutic strategies targeting histone methylation for overcoming therapeutic resistance in NSCLC.
基金：
This work was supported by Yunnan Basic Research Program-Joint Project of Kunming Medical University [202301AY070001-249]. This work is also Supported by Yunnan Provincial Department of Science and Technology Foundation for Youths [202301AU070195].
第一作者机构：[1]Department of Thoracic Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhu Fuze,Yang Xudong,Yang Yanlong,et al.The role of histone methyltransferases in therapeutic resistance of NSCLC[J].Epigenetics.2025,20(1):2536786.doi:10.1080/15592294.2025.2536786.
APA：
Zhu Fuze,Yang Xudong,Yang Yanlong,Tong Xinghe,Jia Jie...&Chen Xiaobo.(2025).The role of histone methyltransferases in therapeutic resistance of NSCLC.Epigenetics,20,(1)
MLA：
Zhu Fuze,et al."The role of histone methyltransferases in therapeutic resistance of NSCLC".Epigenetics 20..1(2025):2536786
